


## Lane OHP Synagis (palivizumab) prior authorization guideline

Updated August 2011



### Notes:

1. Congenital Heart Disease cases are appropriate for RSV prophylaxis if hemodynamically significant, including infants on medications or oxygen to control CHF, moderate to severe pulmonary hypertension, or cyanotic heart disease. This does not include small ASD, VSD, PDA, coarctation, pulmonic stenosis, uncomplicated aortic stenosis, mild cardiomyopathy, or lesions corrected by surgery.
2. Chronic lung disease cases appropriate for prophylaxis include the following conditions when needing oxygen or medical treatment within 6 months of beginning prophylaxis: bronchopulmonary dysplasia, interstitial pulmonary fibrosis, fibrosis of prematurity, Wilson-Mikity Syndrome, chronic respiratory disease of prematurity, cystic fibrosis, asthma, or similar conditions.
3. Medical therapy must have been received within 6 months before the start of the RSV season.
4. Requests for exceptions must include published documentation of effectiveness and estimation of cost-effectiveness for the member's condition.